Subscribe
shutterstock_580492693_akedesign
akedesign / Shutterstock.com
16 March 2020Big PharmaEdward Pearcey

WHO launches international fund to fight COVID-19

The World Health Organization (WHO) has launched a Solidarity Response Fund, offering companies, foundations and individuals the chance to donate to the WHO’s global response to the ongoing COVID-19 pandemic.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
China approves three Gilead remdesivir patents for COVID-19 treatment
27 February 2020   US-based Gilead Sciences has been granted three Chinese patents connected to possible COVID-19 treatment remdesivir, reported He Zhimin, the deputy director of China’s National Intellectual Property Administration.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
China approves three Gilead remdesivir patents for COVID-19 treatment
27 February 2020   US-based Gilead Sciences has been granted three Chinese patents connected to possible COVID-19 treatment remdesivir, reported He Zhimin, the deputy director of China’s National Intellectual Property Administration.

More on this story

Big Pharma
China approves three Gilead remdesivir patents for COVID-19 treatment
27 February 2020   US-based Gilead Sciences has been granted three Chinese patents connected to possible COVID-19 treatment remdesivir, reported He Zhimin, the deputy director of China’s National Intellectual Property Administration.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York